Inclusion Criteria:

          -  Histologically confirmed grade IV supratentorial astrocytoma, IDH wildtype
             (glioblastoma multiforme)

          -  Tumor tissue available for histopathological analysis

          -  Diagnosis must have been made by biopsy or resection lower or equal than 3 months
             prior to study entry

          -  18 - 70 years

          -  Karnofsky performance status greater or equal than 70

          -  Absolute neutrophil count at least 1.5 x 109/L and platelets at least 100 x109/L

          -  Adequate renal function

          -  Adequate hepatic function

          -  Absence of any psychological, familial, sociological or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule.

          -  Females must have negative results for pregnancy tests performed

          -  No breast feeding.

          -  If male, subject must be surgically sterile or practicing a method of contraception

          -  Ability to swallow and take oral medication.

        Exclusion Criteria:

          -  Prior radiotherapy

          -  Prior chemotherapy

          -  Pregnancy or breast feeding

          -  Recent (less than 3 months) severe cardiac disease (NYHA class greater than 1)
             (congestive heart failure, infarction)

          -  History of cardiac arrythmia (multifocal premature ventricular contractions,
             uncontrolled atrial fibrillation, bigeminy, trigeminy, ventricular tachycardia) which
             is symptomatic and requiring treatment, or asymptomatic sustained ventricular
             tachycardia. Asymptomatic atrial fibrillation controlled on medication is allowed.

          -  Cardiac conduction disturbances or medication potentially causing them

          -  Treatment with investigational drugs in 4 weeks prior to or during this study

          -  If the subject has clinically significant and uncontrolled major medical condition(s)

          -  Psychiatric illness/social situation that would limit compliance with study
             requirements

          -  Any medical condition, with the opinion of the study investigator, places the subject
             at an unacceptably high risk for toxicities.

          -  The subject has had another active malignancy within the past 3 years except for any
             cancer in situ that the principal Investigator considers to be cured.

          -  Chronic systemic immune therapy (with the exception of corticosteroids)

          -  Concurrent cytochrome P450 enzyme-inducing anticonvulsant drugs (e.g., phenytoin,
             carbamazepine, phenobarbital, primidone, or oxcarbazepine)

          -  Known glucose-6-phosphate dehydrogenase deficiency

          -  Psoriasis or porphyria

          -  Known hypersensitivity to 4-aminoquinoline compound

          -  Retinal or visual field changes unrelated to the tumor location prior to
             4-aminoquinoline compound use